Best Life Sciences Companies in Pennsylvania, United States

Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.​

Developer of a device for removal of vascular blockages. The company is developing a Lesion Preparation balloon designed to enable more effective removal of blockages in blood vessels and to increase drug uptake when used along with a Drug-Coated Balloon. Their technology has applications in the treatment of Peripheral arterial disease.

Funding rounds

• May 2026Series D$41M
• Feb 2025Series C$15M
• Jan 2024Series C$30M
• Jun 2021Series B$9.5M

Founders & team

Robert GiasolliFounder

Investors

Sectoral, USVP, Synergy Ventures, Ben Franklin Technology Partners, Trinity Capital, M&L Healthcare

Tech stack

CloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookiebotCore-JsDigitalocean Spaces

Developer of gene therapy medicines for neurological diseases. The company leverages precision delivery through Adeno-Associated Virus to target specific cells and tissues, to improve the lives of patients suffering from various central nervous system disorders.

Funding rounds

• May 2026Series A$97M
• May 2024Series A$54M

Founders & team

P GhoroghchianCEO

Investors

8VC, DCVC, Children's Hospital of Philadelphia, Ben Franklin Technology Partners, Gaingels, Modi Ventures

Developer of CAR-T cell therapies for cancer. The KIR-CAR cell therapy provides stimulation to the cell that enhances the T-cell activation and elimination of antigen-negative tumor cells. It provides a product SynKIR-meso for pancreatic cancer, ovarian cancer, and mesothelioma.

Developer of medical devices for hypertension and atherosclerosis treatment. The companies product portfolio includes Virtue Sirolimus-Eluting Balloon and BackBeat Cardiac Neuromodulation Therapy. Virtue Sirolimus-Eluting Balloon delivers delayed-release bioabsorbable particle encapsulated Sirolimus. This can be used for the prevention of restenosis of treated arteries.

Funding rounds

• Jul 2025Post IPO$35M
• Jul 2022Series D$110M
• Dec 2019Venture Debt$20M
• Jul 2019Series B$34M

Founders & team

Darren ShermanPresident

Investors

RTW Investments, Perceptive Advisors, Terumo Medical, SternAegis Ventures, Medtronic, Soleus Capital

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Developer of endovascular catheters for acute venous thromboembolic conditions. It has developed a proprietary endovascular catheter device called BASHIR which is used for the localized infusion of biological fluids. Its BASHI N-X is also intended for the localized infusion of biological fluids into the peripheral vasculature and pulmonary arteries.

Biotech developing small molecule therapies for cancer, guided by clinical experience. The company identifies and develops innovative treatments for various cancers by listening to and learning from clinical experiences. This approach leads to the identification of new therapeutic targets. They focus on translating clinical insights into effective therapies, with a commitment to advancing drug candidates into human trials safely and quickly. Their team possesses diverse skills and expertise to drive the development of transformative cancer treatments. They are dedicated to improving patient outcomes through innovative science and a deep understanding of the clinical landscape. The company is focused on small molecule agents, clinical experience, therapeutic targets, and cancer treatment.

Funding rounds

• Feb 2026Series B$5M
• Aug 2025Series B$1.3M
• Jan 2025Grant (prize money)$1000K
• Aug 2024Series B$5.8M

Founders & team

Christopher NataleCo-FounderTodd RidkyCo-FounderPatrick MooneyCEO

Investors

Kairos Ventures, University of Pennsylvania, HHS, Springboard Enterprises

Noveome is a developer of biologically active molecules for the treatment of Periodontitis and inflammation diseases. It has developed therapies for the regenerative repair of inflamed or damaged tissues. The company's products are clinical applications of a novel secretome that provides a complex solution of molecules secreted from proprietary cells. Secretome solution contains many biologically active molecules, present in physiological concentrations. Secretome (ST266) is Phase 2 for the treatment of periodontitis that is a serious inflammation of the gums that damages the soft tissue and destroys the bone that supports your teeth.

Peptilogics has developed antibiotics to target Multi-drug resistant bacteria. The company has developed eCAPS technology to produce novel antibiotics for drug-resistant bacteria. It acts by disrupting the bacterial membrane and inactivating it. It has shown effectiveness against the ESKAPE pathogens, both gram-positive and gram-negative, that cause the majority of resistant hospital-acquired infections.

Funding rounds

• Oct 2025Series B$78M
• Jan 2025Grant (prize money)$3.3M
• Aug 2022Grant (prize money)$499.4K
• Sep 2021Grant (prize money)$698.7K

Founders & team

Jonathan SteckbeckFounder | President | CEO

Investors

Presight Capital, Founders Fund, HHS, AMR Action Fund, Narya, Beyond Venture Partners

Tech stack

All In One SeoBugherdCdnjsChart.JsCloudflareCloudflare Bot Management

Verrica is a developer of therapeutic solutions for skin diseases such as molluscum contagiosum, and others. It has developed a lead product, VP-100 is a topical film forming formulation, indicated for molluscum contagiosum and Verruca Vulgaris (common warts and plantar warts). VP-100 has completed phase II trials and the company is initiating pivotal phase III trials for Molluscum contagiosum. The company is also developing treatments for additional common dermal indications including Actinic Keratosis and Seborrheic Keratosis.

Funding rounds

• Nov 2025Post IPO$50M
• Feb 2018Series B$20M
• Dec 2017Series A$5M
• Dec 2015Series A$2.4M

Founders & team

Ted WhitePresident & CEO

Investors

Pharus, Perceptive Advisors, Westwicke, Orbimed, PBM Capital, avenuealtd.com

Tech stack

Apple Icloud MailCloudflareCloudflare Browser InsightsCore-JsElementorFont Awesome

VenatroRx is a US-based, clinical stage biotech developing beta-lactamase inhibitors for DR infections. The company focuses on beta-lactamase inhibitors that target penicillin binding proteins to overcome bacterial resistance to beta-lactam drugs. Their lead candidate, VNRX‐5133, is an intravenous beta‐lactamase inhibitor. VNRX‐5133 is designed to inhibit the four major classes of beta‐lactamase resistance enzymes, including metallo‐beta‐lactamases (MBL). VenatoRx plans to use the drug to inhibit bacterial resistance mechanisms, enabling a paired beta-lactam antibiotic to kill the microorganisms. The other candidate is VNRX‐7145, an orally bioavailable beta‐lactamase inhibitor that is in late preclinical testing. In Jul.2017, the company was awarded $9.4M from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator)

Developer of wireless ECG monitor for personal health monitoring use. The monitor is indicated for use on patients who may be asymptomatic. It can also be used for patients who may suffer from transient symptoms. These symptoms include palpitations, shortness of breath, dizziness, and fatigue. The monitor is intended for use by patients eighteen years or older. The system is not yet cleared for other indications.

Funding rounds

• Nov 2025Series B$15.1M
• Jun 2024Series B$18.4M
• Sep 2021Series A$78.2K
• Jul 2020Series A$3.2M

Founders & team

David RobinsCo-FounderRobert Van TasselCo-FounderRobert SchwartzCo-Founder

Investors

Paragon Equity Partners, Brightstone Venture Capital

Tech stack

Wix EcommerceWixReactGoogle CloudPolyfillLodash